RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer - Takeaways - MDSpire

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

  • By

  • June 1, 2026

  • 5 min

Share

  • 1

    Daraxonrasib, an oral RAS(ON) inhibitor, significantly improves overall survival in patients with previously treated metastatic pancreatic cancer.

  • 2

    In the RASolute 302 trial, median overall survival was 13.2 months for daraxonrasib compared to 6.7 months for chemotherapy.

  • 3

    Daraxonrasib demonstrated a 31.6% objective response rate, significantly higher than the 11.2% seen with chemotherapy.

  • 4

    The FDA has allowed an expanded access program for daraxonrasib, indicating its potential as a new standard of care.

  • 5

    The trial results suggest a paradigm shift in treating pancreatic cancer, particularly for patients with KRAS mutations.

Original Source(s)

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

  • by

  • June 1, 2026

Related Content

Association between EAT-Lancet diet adherence and cancer incidence/mortality: a systematic review and meta-analysis

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review